Antisense therapeutics

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 519-528

  Agrawal, Sudhir ^a   Zhao, Qiuyan ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; NUCLEOTIDE;

ANIMAL; DRUG COMBINATION; DRUG DESIGN; HUMAN; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 0032134464     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80129-4     Document Type: Article

References (52)

1. Agrawal S: Antisense oligonucleotides: towards clinical trials Trends Biotechnol 1996, 14:376-387.
2. Akhtar S, Agrawal S: In vivo studies with antisense oligonucleotide. Trends Pharmacol Sci 1997, 18:12-18.
3. Bennett CF: Antisense oligonucleotides: is the glass half full or half empty? Biochem Pharmacol 1998, 55, 9-19. This is an excellent review in which present status and future issues are discussed with respect to antisense therapeutics.
4. Agrawal S: Antisense therapeutics. Edited by Agrawal S. New Jersey: Humana Press; 1996.
5. Crooke S (Ed): Antisense Research and Application. New York: Springer; 1998.
6. Wickstrom E: Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Edited by Wickstrom E. Marcel Dekker: New York; 1998.
7. Ciba Foundation Symposium: Oligonucleotides as Therapeutic Agents, New York: John Wiley & Sons; 1997.
8. Stein CA, Krieg AM (Eds): Applied Antisense Oligonucleotide Technology. New York: Wiley-Liss; 1998.
9. Chen L, Agrawal S, Zhou W, Zhang R, Chen J: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998, 95:195-200. Evidence of antisense activity is clearly demonstrated at the RNA and protein level. In addition, the impact of the down-regulation of the targeted mRNA (mdm2) has been demonstrated on secondary (p53) and tertiary (p21) products.
10. Branch AD: A good antisense molecule is hard to find. Trends Pharmacol Sci 1998, 23:39-50.
11. Agrawal S, Tan W, Cai Q, Xie X, Zhang R: In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev 1997, 7:245-249.
12. Phillips JA, CRaig SJ, Bayley D, Christian RA, Geary R, Nicklin PL: Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. J Pharmacol Exp Ther 1996, 278:1313-1317.
13. Grindel JM, Musick TJ, Jiang Z, Roskey A, Agrawal S: Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in Cynomolgus Monkeys following intravenous infusion. In Antisense Nucleic Acid Drug Dev 1998, 8:43-52.
14. Martin RR: Early clinical trials with GEM91, a systemic oligodeoxynucleotide. In Applied Antisense Oligonucleotide Technology. Edited by Stein CA and Krieg AM. New York: Wiley-Liss; 1998:387-393.
15. Glover JM, Leeds JM, Mant TGK, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR Jr: Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997, 282:1173-1180.
16. Nicklin PL, Craig SJ, Philips JA: Pharmacokinetic properties of phosphorothioates in animals- absorption, distribution, metabolism and elimination. In Antisense Research and Application. Edited by Crooke S. New York: Springer; 1998:141-168.
17. Agrawal S, Zhang R: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administration in experimental animals. In Antisense Research and Application. Edited by Crooke S. New York: Springer; 1998:525-541.
18. Temsamani J, Roskey A, Chaix C, Agrawal S: In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Antisense Nucleic Acid Drug Dev 1997, 7:159-165.
19. Cummins LL, Winniman M, Gaus HJ: Phosphorothioate oligonucleotide metabolism: characterization of the 'N+'-mer by CE and HPLC-ES/MS. Bioorg Med Chem Lett 1997, 7:1225-1230.
20. Butler M, Stecker K. Bennett CF: Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 1997, 77:379-388. This demonstrates the advantage of in vivo cellular uptake of oligonucleotides by employing various methodologies.
21. Carome MA, Kang YH, Bohen EM, Nicholson DE, Carr FE, Kiandoli LC, Brummel SE, Yuan CM: Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo. Nephron 1997, 75:82-87.
22. Bijsterbosch MK, Manoharan M, Rump ET, De Vrueh RL, van Veghel R, Tivel KL, Biessen EA, Bennett CF, Cook PD, van Berkel TJ: In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 1997, 25:3290-3296.
23. Zhao Q, Zhou R, Temsamani J, Zhang Z, Roskey A, Agrawal S: Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. Antisense Nucl Acid Drug Dev 1998:in press.
24. Agrawal S, Zhao Q, Jiang Z, Oliver C, Giles H, Heath J, Serota D: Toxicological Effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. In Antisense Nucleic Acid Drug Dev 1997, 7:575-584.
25. Henry SP, Monteith D, Levin AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997, 12:395-408.
26. Henry SP, Boite H, Auletta C, Kornbrust DJ: Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 1997, 120:145-155.
27. Levin AA, Monteith DK, Leeds JM, Nicklin PL, Geary RS, Butler M, Templin MV, Henry SP: Toxicity of oligonucleotide therapeutic agents. In Antisense Research and Application. Edited by Crooke S. New York: Springer; 1998:169-215.
28. Agrawal S, Zhao Q: Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev 1998, 8:135-139. A demonstration of the advantage of the use of modified oligonucleotides over phosphorothioate oligonucleotides on observed toxicity.
29. Schechter PJ, Martin RR: Safety and tolerance of phosphorothioate in humans. In Antisense Research and Application. Edited by Crooke S. New York: Springer; 1998:233-241.
30. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G: Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol 1993, 45:2037-2043.
31. Krieg AM: Leukocyte stimulation by oligodeoxynucleotides. In Applied Antisense Oligonucleotide Technology. Edited by Stein CA and Krieg AM. New York: Wiley-Liss; 1998:431-448. An in depth review of the CpG motif and its role in immune stimulation.
32. Zhao Q, Temsamani J, Iadarola PL, Jiang ZW, Agrawal S: Effect of different chemical modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 1996, 51:173-182.
33. Klinman DM, Yi A, Beaucage SL, Conover J, Krieg AM: CpG motifs expressed by bacterial DNA rapidly induced lymphocytes to secrete IL-6, IL-12 and IFN-γ. Proc Natl Acad Sci USA 1996, 93:2879-2883.
34. Zhao Q, Temsamani J, Zhou R, Agrawal S: Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev 1997, 7:495-502. Evidence of in vivo cytokine induction following administration of oligonucleotides. The pattern and kinetics of cytokine induction depends upon dose, sequence and animal strain employed.
35. Pisetsky DS: Immune activation by bacterial DNA: a new genetic code. Immunity 1996 5:303-310.
36. Hendrzak JA, Brunda MJ: Interleukin-12:biological activity, therapeutic utility, and role in disease. Lab Invest 1995, 72:619-637.
37. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL: The good, the bad, and the ugly' The role of chemokines in models of human disease. J Immunol 1996, 156:3583-3590.
38. Agrawal S, Temsamani J: Oligonucleotide as antiviral agents. In Antisense-from Technology to Therapy. Edited by Schlingensiepen R, Brysch W, Schlingensiepen KH. Gottingen: Blackwell Science; 1997:224-250.
39. Crooke ST: Treatment of retinitis induced by cytomegalovirus using intravitral formivirsen (ISIS 2922). In Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Edited by Wickstrom E. New York: Marcel Dekker; 1998:353-362.
40. F Calvo LM: Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmcol 1996, 10:97-115.
41. Calabretta B, Skorski T: Targeting c-myc in leukemia. Anticancer Drug Des 1997, 12:373-381.
42. Gewirtz AM: Antisense oligonucleotide therapeutics for human leukemia. Curr Opin Hematol 1998, 5:59-71.
43. Monia BP: First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des 1997, 12:327-339.
44. Geiger T, Muller M, Dean NM, Fabbro D: Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998, 13:35-45.
45. Tortora G, Caputo R, Damiano V, Bianco R, Pepe S, Bianco AR, Jiang Z, Agrawal S, Ciardiello F: Synergistric inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA 1997, 94:12586-12591.
46. Cowsert LM: In vitro and in vivo activity of antisense inhibitiors of ras: potential for clinical development. Anticancer Drug Design 1997, 12:359-371.
47. Cotter FE: Human bcl-2 antisense therapy for lymphomas. In Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Edited by Wickstrom E. New York: Marcel Dekker; 1998:169-190.
48. Veal GJ, Agrawal S, Byrn RA: Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. Antiviral Res 1998, 38:63-73.
49. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G: c-Myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998, 58:283-289.
50. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and transformation by a specific oligonucleotide. Proc Natl Acad Sci USA 1978, 75:280-284.
51. Wurl P, Meye A, Schmidt H, Lautenschlager C, KAIthoff H, Path FW, Taubert H: High prognostic significance of mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998, 16:1183-1185.
52. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H: The mdm2 oncogene over-expression in chronic lymphocytic leukemia and low grade lymphoma of B cell origin. Blood 1994, 84:3158-3165.